Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
33.24
+1.51 (4.76%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
33.24
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 5:25 PM EDT
NewAmsterdam Pharma Company N.V., kechki bosqichdagi biofarmatsevtika kompaniyasi, kardiyometabolik kasalliklarga chalingan bemorlarga g'amxo'rlikni yaxshilash uchun terapiyalarni ishlab chiqadi. Kompaniya Obicetrapibni ishlab chiqmoqda, bu og'iz orqali qabul qilinadigan, kam dozali xolesteril ester transfer proteini (CETP) ingibitori bo'lib, u turli klinik sinovlarda monoterapiya va ezetimib bilan kombinatsiyalangan terapiya sifatida LDL-C ni kamaytirish uchun ishlatiladi. Kompaniya, shuningdek, Altsgeymer kasalligi uchun 2a faza klinik sinovida bo'lgan Obicetrapibni ishlab chiqmoqda. NewAmsterdam Pharma Company N.V. Niderlandiyaning Naarden shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director |
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | CEO, President & Executive Director |
| Mr. Chris Deluzio | Executive Vice President of Sales Enterprise Operations |
| Mr. Douglas F. Kling | Chief Operating Officer |
| Mr. Matthew Philippe | Executive VP & Head of Investor Relations |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer |
| Mr. Michael F. Marino Esq. | Chief Legal Officer & Corporate Secretary |
| Ms. Juliette Audet M.B.A., M.Sc. | Chief Strategy & Business Officer |
| Ms. Louise Kooij | Chief Accounting Officer |
| Ms. Maryellen McQuade | Chief People Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-05 | S-8 | nams-20260605.htm |
| 2026-06-03 | 8-K | nams-20260602.htm |
| 2026-05-07 | 8-K | nams-20260507.htm |
| 2026-05-07 | 10-Q | nams-20260331.htm |
| 2026-05-06 | DEF 14A | nams-20260506.htm |
| 2026-05-06 | ARS | nams_2025_10-k_ars.pdf |
| 2026-04-24 | 8-K | nams-20260420.htm |
| 2026-04-20 | PRE 14A | nams-20260420.htm |
| 2026-03-02 | 8-K | nams-20260302.htm |
| 2026-02-18 | S-8 | nams-20260218.htm |